INS and Hypoglycemia: Our network meta-analysis suggested that all GLP-1 RAs significantly increase the risk of hypoglycemia compared with placebo (except for albiglutide), and reduce the risk of hypoglycemia compared with insulin (except for dulaglutide) and SU.